Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib PK interaction with Rifampin
NCT02199392Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in thyroid cancer, sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve. Started Nov 2011; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT02199392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199392.